This company has been acquired
Jounce Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Jounce Therapeutics has a total shareholder equity of $183.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $212.6M and $29.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$189.54m |
| Equity | US$183.11m |
| Total liabilities | US$29.44m |
| Total assets | US$212.55m |
Recent financial health updates
We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate
Jan 04
Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Sep 20Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Jun 16We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business Growth
Feb 23We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash Wisely
May 03Recent updates
We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate
Jan 04Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Sep 20Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Jun 16We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business Growth
Feb 23Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts
Dec 16News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Aug 07Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jul 13Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenues
Jun 16Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's Why
Jun 12Jounce Therapeutics EPS beats by $0.01, misses on revenue
May 04We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash Wisely
May 03Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price Gain
Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Mar 02Enrollment underway in Jounce Therapeutics' early-stage JTX-8064 study in solid tumors
Jan 13Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?
Jan 13
Jounce Therapeutics: A Potential Roller Coaster
Dec 31A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO Remuneration
Dec 15Financial Position Analysis
Short Term Liabilities: JNCE's short term assets ($197.2M) exceed its short term liabilities ($23.6M).
Long Term Liabilities: JNCE's short term assets ($197.2M) exceed its long term liabilities ($5.9M).
Debt to Equity History and Analysis
Debt Level: JNCE is debt free.
Reducing Debt: JNCE has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JNCE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: JNCE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 26.2% each year